Kargluminsyre Waymade

Carglumic acid, the active ingredient in Kargluminsyre Waymade, is a urea cycle agent presented as an oral formulation for oral use. It is indicated for the treatment of hyperammonemia associated with N‑acetylglutamate synthase deficiency and other urea cycle disorders, helping to lower elevated plasma ammonia levels.

GNH USA supplies Kargluminsyre Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Kargluminsyre Waymade is a urea cycle agent used to manage conditions characterized by impaired ammonia detoxification. - Hyperammonemia due to N‑acetylglutamate synthase deficiency: reduces plasma ammonia concentrations and supports the urea cycle. - Urea cycle disorders: activates carbamoyl phosphate synthetase I to restore normal ammonia metabolism.

Carglumic acid is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Vomiting - Abdominal pain or discomfort - Diarrhea - Headache - Altered taste perception

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Worsening hepatic encephalopathy - Metabolic acidosis - Hyperuricemia - Seizures - Significant liver function test abnormalities

Carglumic acid should be used with careful clinical monitoring. - Monitor plasma ammonia levels regularly: adjust therapy based on results. - Assess liver function before and during treatment: watch for signs of hepatic decompensation. - Adjust dosing in renal impairment: reduced clearance may require modification. - Avoid use in patients with known hypersensitivity to carglumic acid or excipients. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Carglumic acid may interact with other agents that affect ammonia metabolism or acid‑base balance.

Major Interactions (Avoid): - Sodium phenylbutyrate: combined use can increase risk of metabolic acidosis. - Liver transplant immunosuppressants (e.g., tacrolimus): may alter ammonia handling and require close monitoring.

Moderate Interactions (Monitor Closely): - High‑protein diet: may reduce the drug's efficacy in lowering ammonia. - Renal replacement therapy (dialysis): can affect drug clearance, necessitating dose adjustments. - Other ammonia‑scavenging agents (e.g., sodium benzoate): monitor ammonia levels to avoid over‑correction.